Molbio Diagnostics Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹116(14.37%)
Premium (ELP)
Molbio Diagnostics Limited's completed its IPO journey with a successful listing on NSE, BSE on Aug 17, 2026. The public offering mobilized 1,16,46,246 Shares in total capital, comprising 24,80,246 Shares in fresh equity and ₹742.45 Cr in Offer for Sale shares from existing stakeholders.
The offering was conducted within the price band of ₹768 to ₹807, with minimum application lots of 18 shares. Investor participation during the Aug 10, 2026 to Aug 12, 2026 subscription window determined the final allocation pattern.
The basis of allotment was announced on Aug 13, 2026, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Innovative Diagnostic Technology: Company nu flagship molecular testing platform rapid ane accurate diagnosis aape che, je healthcare sector ma strong differentiation create kare che.
- Recurring Consumable Revenue: Devices install thaya pachhi test kits ni regular demand ave che, je company ne stable ane repeat income aape che.
- Strong Financial Growth: Recent years ma revenue ane profit ma fast growth joi male che, je business scalability ane demand darshave che.
- High Dependence on Government Orders: Revenue no moto hissa government ane institutional clients mathi ave che, je policy changes thi impact thai shake che.
- Product Concentration Risk: Company nu major revenue limited diagnostic tests (especially TB related) par dependent che, je diversification risk create kare che.
- Working Capital Intensive: Inventory ane operations maintain karva ma heavy working capital joiye, je cash flow par pressure muki shake che.
- Sriram Natarajan
- Dr. Chandrasekhar Bhaskaran Nair
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Exxora Trading LLP
Molbio Diagnostics Limited
Kfin Technologies Limited